Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin

Abstract excerpt

Abstract Small cell lung cancer (SCLC) is generally regarded as very difficult to treat, mostly due to the development of metastases early in the disease and a quick relapse with resistant disease. SCLC patients initially show a good response to treatment with the DNA damaging agents cisplatin and etoposide. This is, however, quickly followed by the development of resistant disease, which urges the development of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer therapeutics and mechanisms
• Share to Lung Cancer Research Studies
• Share to Neuroendocrine Tumor Research Advances